Details for Patent: D459798

Summary for Patent: D459798

Title:	Pill tablet
Abstract:
Inventor(s):	Christian Desesquelle, Philippe Becourt
Assignee:	Aventis Pharma SA
Application Number:	US29/148,657
Patent Claim Types: see list of patent claims

US Design Patent D459,798 Landscape: What “Ornamental Design for Pill Tablet” Covers and How Broad the Right Is

Executive summary. United States design patent D459,798 protects only the ornamental appearance of a pill tablet as depicted in its drawings. Scope is limited to the specific visual design disclosed (shape, surface features, markings, and configuration) and does not cover active ingredient, formulation, manufacturing process, composition, method of use, or any non-ornamental functionality. Enforceability against third-party products turns on whether an accused tablet shows overall visual similarity to the patented design as judged by ordinary observers, typically using claim construction focused on the figures and line drawings rather than written claim language.

What exactly does US patent D459798 claim: “ornamental design for pill tablet” scope?

Direct answer. D459,798’s claim is a design claim: “The ornamental design for pill tablet, substantially as shown and described.” Under US design patent practice, that phrase means the protected subject matter is the ornamental design embodied in the patent’s drawings.

Why the claim is narrow by definition

Design patents differ from utility patents because:

• There is no functional claim to composition, dosing, delivery, or manufacturing.
• The claim does not enumerate structural elements in words. Scope is determined by the drawings (front/back/side views and any perspective views).
• “Substantially as shown” constrains infringement to designs that are substantially similar in overall appearance.

What is covered vs. not covered

Covered (potentially):

• Tablet overall look: geometry and proportions shown in the drawings.
• Surface ornamentation: embossed or debossed features, indents, ribs, texture patterns visible in the figures.
• Edge and corner detailing: chamfers, bevels, and contours if shown.
• Color and plating only to the extent the design is depicted in the patent. Many design patents for tablets use black-and-white line drawings, which generally means color is not claimed unless explicitly shown.

Not covered:

• Chemical composition of the drug (active ingredient selection, excipients).
• Tablet formulation properties (disintegration, dissolution, coating composition).
• Manufacturing process steps.
• Functional design choices (e.g., breaking characteristics) unless they manifest as ornamental features in the drawings.
• Drug packaging, labeling, imprinting meant for legibility, unless the imprint is part of the depicted ornamental design.

Claim language implications: “substantially as shown and described”

Courts interpret design patent scope by comparing:

• the claimed design (as depicted),
• against the accused product’s overall appearance.

Because D459,798 includes no text limitations beyond the “substantially as shown,” the figures drive scope.

How do US design patents like D459798 get interpreted in infringement cases?

Direct answer. Infringement of a US design patent is assessed through ordinary observer and often point of novelty analyses, with emphasis on the visual impression created by the claimed design.

What matters most in practice

For D459,798, enforcement strength turns on:

1. Accuracy and completeness of the drawings: if the drawings omit certain views or features, those features are hard to assert against a design.
2. Number and prominence of ornamental features: complex or distinctive motifs widen the room for distinguishing prior art and limiting claim scope.
3. Presence of common tablet traits: generic tablet shapes (round, oval, capsule-shaped outlines) can reduce novelty if broadly present in prior art.

Practical infringement test

• If an accused tablet’s overall visual appearance is close to the patented design, a factfinder can find infringement.
• If an accused tablet differs in prominent ornamental aspects, it can avoid infringement even if it uses the same general outline category.

What prior art and prosecution context likely affect the scope of D459798?

Direct answer. Design patents are constrained by existing designs in the same “visual space” of pill tablet ornamentation. Even with a valid design claim, earlier designs can:

• narrow effective enforceability,
• create defenses of anticipation or obviousness if challenged.

How prior art is used for design patents

Unlike utility patents where claim elements map to prior art limitations, design patent validity and scope rely on:

• visual similarity between the patented design and prior designs,
• whether the claimed design was new and non-obvious at filing,
• and how much of the design is truly distinctive.

Typical risk areas for pill tablet designs

Design patents covering tablet appearance often face crowded prior art around:

• standard outline silhouettes (round, oval, capsule shape),
• basic embossing patterns,
• generic letter/number impressions,
• shallow textures or common bevels.

If D459,798 is built from common features, enforcement can weaken because the “real” novelty may be narrower to a smaller configuration of details.

What other patents might cover the same pill tablet product besides D459798?

Direct answer. A pill tablet product can have an overlapping patent stack:

• Utility patents for composition, polymorphs, coatings, or manufacturing,
• Design patents for tablet appearance and/or packaging visuals,
• Method-of-use patents for dosing regimens,
• Trademark and trade dress issues for branding.

D459,798 only addresses ornamental tablet design, so it sits at the perimeter of a broader IP estate.

Common related IP categories that coexist with tablet design patents

• Coating design or “taste masking” product forms (usually utility).
• Scoring lines or break features (can be argued as ornamental if depicted, but often functionality dominates).
• Imprint style (ornamental if depicted and claimed as part of the design).
• Color/shape marketing (design patents or trade dress depending on facts).

How long does D459798 remain enforceable in the US?

Direct answer. Design patent term in the US depends on the filing date. For design patents, the term is generally 15 years from grant for patents filed before certain rule changes; for others, it can differ. Without the filing or issue date for D459,798, a precise term cannot be stated.

What can be stated from claim scope alone: D459,798 is a design right and its remaining life is determined under 35 USC rules applicable to its filing date, not by regulatory exclusivity or Orange Book listings.

What is the Orange Book status relevance for D459798?

Direct answer. D459,798 is a design patent, and Orange Book listings typically include patents tied to the drug product that meet listing requirements. Design patents are sometimes not listed, and when listed they still do not create generic launch barriers the same way some utility patents can.

Key operational point: Regulatory exclusivity and Orange Book patent listing strategy is driven by:

• NDA/BLA context,
• whether the design patent is listed for the relevant drug,
• and whether a generic applicant challenges it via Paragraph IV (or otherwise addresses it).

Without the Orange Book listing record for D459,798, no listing status can be asserted here.

How strong is the patent estate for a pill tablet based on a single design claim?

Direct answer. The strength of D459,798 as an asset is driven by:

• distinctiveness of the drawings,
• breadth of the “substantially as shown” match to likely competitors’ tablets,
• and how much the relevant market designs resemble the patented ornamental configuration.

A single design patent can be strong if:

• the design is highly distinctive,
• competitors adopt close visual variants,
• and the drawings show clear novel aspects.

A single design patent can be weak if:

• many products already share similar outlines and ornamentation,
• the novelty resides in minor details that competitors omit or change.

What generic entry risks exist for designs covered by D459798?

Direct answer. Generic entry risk from a design patent is mainly about whether the generic’s commercial tablet design is visually close enough to infringe.

How design patents change the generic strategy

Generic applicants may respond by:

• changing ornamental appearance (shape, embossing, imprint, surface texture),
• using different tablet outlines or imprint structures,
• changing color or coating appearance (if depicted and material).

Unlike utility patents, the pathway to avoid infringement is often design-around rather than formulation-around.

Which companies are likely affected by D459798?

Direct answer. D459,798’s coverage is not defined by an active ingredient or applicant in the claim language. The affected parties are any manufacturers that commercialize pill tablets whose overall ornamental appearance matches the design as shown.

Without the patent’s assignee and without the identity of the drug product linked to the design patent, company-level identification cannot be produced from the claim alone.

What design-around strategies can avoid infringement of a pill tablet design?

Direct answer. To reduce infringement exposure under “overall appearance,” competitors typically shift one or more of the most prominent ornamental features in the drawings.

Most effective design-around levers (conceptual)

• Alter the outline proportions (relative width/height, edge curvature) if they drive the impression.
• Replace or relocate embossed/debossed motifs (including orientation and depth).
• Change surface texture patterns or remove them.
• Modify corner/edge treatments (bevels, chamfers, radius).

Minor changes that do not change the overall visual impression are more likely to fail.

What patent litigation affects enforcement of D459798?

Direct answer. Litigation risk depends on the existence of enforcement actions involving D459,798, but the claim text alone does not provide litigation status, forum, or case identifiers. No litigation-specific facts can be stated here.

Key Takeaways

• D459,798 is a design-only right: it protects the ornamental appearance of a pill tablet, not the drug product’s composition, dosing, or manufacturing.
• The claim scope is effectively determined by the patent drawings because the claim contains only “substantially as shown and described.”
• Infringement turns on overall visual similarity to the patented design as perceived by ordinary observers, with the patented figure set as the anchor.
• Generic risk is largely design-around driven: competitors can often reduce exposure by changing prominent ornamental features visible in the patent.
• The asset’s real-world enforceability depends on distinctiveness vs. prior tablet designs and how close competitor tablets are in outward appearance.

FAQs

1) Can D459,798 stop a generic even if the active ingredient is the same?
Yes, in principle, a design patent can restrict marketing of a tablet whose ornamental appearance infringes the claimed design, regardless of active ingredient, but only if the accused tablet is visually close to the drawings.

2) Do design patents like D459,798 cover the tablet imprint text?
Only if the imprinting and its ornamental presentation are shown in the patent drawings and thereby part of the claimed design’s overall appearance.

3) If a generic changes the tablet outline slightly, does that avoid infringement?
Not automatically. The test is whether the overall visual impression remains substantially similar to the claimed design.

4) Are method-of-use or formulation patents needed to protect the pill product if there is already a design patent?
Often yes for composition or performance, because D459,798 does not claim those features.

5) How does the filing date of a design patent affect its remaining life?
Design patents have specific term rules tied to filing/grant dates under US law; exact remaining life requires the patent’s dates, which are not provided in the claim text.

References (APA)

1. 35 U.S.C. § 171. (n.d.). Design patents.
2. 35 U.S.C. § 154. (n.d.). Contents and term of patents.
3. Manual of Patent Examining Procedure (MPEP). (n.d.). Design patents and claim interpretation.

Drugs Protected by US Patent D459798

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: D459798

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 1861	Mar 26, 2001